me is dense with biostats...

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

peter90036

not out fishing
10+ Year Member
7+ Year Member
Joined
Jul 13, 2005
Messages
254
Reaction score
0

Members don't see this ad.
http://jama.ama-assn.org/cgi/content/short/300/18/2134

Results
A total of 154 atherosclerotic events occurred: 68 in the aspirin group (13.6 per 1000 person-years) and 86 in the nonaspirin group (17.0 per 1000 person-years) (hazard ratio
, 0.80; 95% confidence interval [CI], 0.58-1.10; log-rank test, P = .16).

The combined end point of fatal coronary events and fatal cerebrovascular events occurred in 1 patient (stroke) in the aspirin group and 10 patients (5 fatal myocardial infarctions and 5 fatal strokes) in the nonaspirin group (HR, 0.10; 95% CI, 0.01-0.79; P = .0037). A total of 34 patients in the aspirin group and 38 patients in the nonaspirin group died from any cause (HR, 0.90; 95% CI, 0.57-1.14; log-rank test, P = .67). The composite of hemorrhagic stroke and significant gastrointestinal bleeding was not significantly different between the aspirin and nonaspirin groups.

Conclusion
In this study of patients with type 2 diabetes, low-dose aspirin as primary prevention did not reduce the risk of cardiovascular events.

.......

me = huh? 68 vs 86, 1 vs 10 ...

i dont get it, why is the conclusion that it does not reduce the risk?
 
Last edited:

It'sElectric

Full Member
10+ Year Member
Joined
Dec 5, 2005
Messages
1,501
Reaction score
6
http://jama.ama-assn.org/cgi/content/short/300/18/2134

Results
A total of 154 atherosclerotic events occurred: 68 in the aspirin group (13.6 per 1000 person-years) and 86 in the nonaspirin group (17.0 per 1000 person-years) (hazard ratio
, 0.80; 95% confidence interval [CI], 0.58-1.10; log-rank test, P = .16).

The combined end point of fatal coronary events and fatal cerebrovascular events occurred in 1 patient (stroke) in the aspirin group and 10 patients (5 fatal myocardial infarctions and 5 fatal strokes) in the nonaspirin group (HR, 0.10; 95% CI, 0.01-0.79; P = .0037). A total of 34 patients in the aspirin group and 38 patients in the nonaspirin group died from any cause (HR, 0.90; 95% CI, 0.57-1.14; log-rank test, P = .67). The composite of hemorrhagic stroke and significant gastrointestinal bleeding was not significantly different between the aspirin and nonaspirin groups.

Conclusion
In this study of patients with type 2 diabetes, low-dose aspirin as primary prevention did not reduce the risk of cardiovascular events.

.......

me = huh? 68 vs 86, 1 vs 10 ...

i dont get it, why is the conclusion that it does not reduce the risk?



I could be wrong, but that conclusion is correct. It didn't significantly reduce the number of cardiovascular events, but it DID significantly reduce the number of fatal CV events.

It's stats...
 

peter90036

not out fishing
10+ Year Member
7+ Year Member
Joined
Jul 13, 2005
Messages
254
Reaction score
0
is it because in case of the events the P > 0.05 while in fatal the P is <0.05 which makes this conclusion valid ?
 
Top